Eli Lilly and Company $LLY Shares Sold by State of Alaska Department of Revenue

Key Points

• The State of Alaska Department of Revenue has reduced its holdings in Eli Lilly and Company by 3.9%, now owning 92,571 shares valued at approximately $72.16 million.
• Eli Lilly reported a quarterly earnings per share of $6.31, exceeding expectations, with revenue growth of 37.6% year-over-year, totaling $15.56 billion.
• Analysts have varied opinions on Eli Lilly's stock, with recent downgrades from "strong-buy" to "hold" ratings, while the stock has a consensus price target of $939.61.

State of Alaska Department of Revenue decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,571 shares of the company's stock after selling 3,768 shares during the period. Eli Lilly and Company comprises 0.8% of State of Alaska Department of Revenue's investment portfolio, making the stock its 12th biggest position. State of Alaska Department of Revenue's holdings in Eli Lilly and Company were worth $72,161,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares during the period. Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $43,000. MassMutual Private Wealth & Trust FSB increased its holdings in Eli Lilly and Company by 9.3% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 3,618 shares of the company's stock worth $2,988,000 after purchasing an additional 309 shares during the period. Finally, Versant Capital Management Inc increased its holdings in Eli Lilly and Company by 68.0% during the 1st quarter. Versant Capital Management Inc now owns 1,961 shares of the company's stock worth $1,620,000 after purchasing an additional 794 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $724.73 on Friday. The stock has a fifty day moving average price of $734.15 and a 200 day moving average price of $767.20. The stock has a market cap of $685.93 billion, a PE ratio of 47.37, a P/E/G ratio of 0.99 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on LLY shares. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Guggenheim decreased their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Insider Activity

In related news, Director Gabrielle Sulzberger purchased 117 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.